Tango Therapeutics

TNGX

Market cap $1.4B

BOSTON, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), today announced that Adam Crystal, M.D., Ph.D., President of Research & Development at Tango Therapeutics, is scheduled to participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on Wednesday, December 3 at 1:30pm ET.

Tango Therapeutics, Inc. is initiated with a Buy rating due to strong progress with its lead PRMT5 inhibitor, vopimetostat, for MTAP-deleted cancers. TNGX reported positive phase 1/2 results in 2nd-line MTAP-deleted pancreatic cancer, doubling median progression-free survival and objective response rate versus historical controls. A pivotal trial for vopimetostat in 2nd-line MTAP-deleted pancreatic cancer patients is set for 2026, with additional combination and expansion studies planned for broader indications.

The mean of analysts' price targets for Tango Therapeutics (TNGX) points to a 46.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Tango Therapeutics, Inc. (TNGX) came out with quarterly earnings of $0.13 per share, beating the Zacks Consensus Estimate of $0.01 per share. This compares to a loss of $0.27 per share a year ago.

The average of price targets set by Wall Street analysts indicates a potential upside of 52.2% in Tango Therapeutics (TNGX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Venture capital fund Third Rock Ventures IV, L.P. sold 477,401 shares of Tango Therapeutics on October 23, 2025.

Tango Therapeutics (TNGX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Tango Therapeutics, Inc. (NASDAQ:TNGX ) Discusses Positive Clinical Data and Development Plans for Vopimetostat in MTAP-deleted Cancers October 23, 2025 8:30 AM EDT Company Participants Elizabeth Hickin - VP of IR & Corporate Communications Barbara Weber - President, CEO & Director Adam Crystal - President of Research & Development Conference Call Participants Eric Schmidt - Cantor Fitzgerald & Co., Research Division Michael Schmidt - Guggenheim Securities, LLC, Research Division Maurice Raycroft - Jefferies LLC, Research Division Peter Lawson - Barclays Bank PLC, Research Division Robert Driscoll - Wedbush Securities Inc., Research Division Kelsey Goodwin - Piper Sandler & Co., Research Division Yuan Zhi - B. Riley Securities, Inc., Research Division Presentation Operator Good day.

Tango Therapeutics Inc. (NASDAQ:TNGX) revealed data from its ongoing Phase 1/2 study of vopimetostat (TNG462) in patients with MTAP-deleted cancers.

Financing participants include Farallon Capital Management, TCGX, Balyasny Asset Management, Woodline Partners LP, Nextech, Invus, Adage Capital Management LP, Boxer Capital Management, Logos Capital, Nantahala Capital, accounts advised by T. Rowe Price Investment Management, Inc., and a large institutional investor Financing participants include Farallon Capital Management, TCGX, Balyasny Asset Management, Woodline Partners LP, Nextech, Invus, Adage Capital Management LP, Boxer Capital Management, Logos Capital, Nantahala Capital, accounts advised by T. Rowe Price Investment Management, Inc., and a large institutional investor